Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Gabriel Etienne, MD, PhD, Carmino De Souza, MD, PhD, Mineo Kurokawa, MD, Matt Kalaycio, MD, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, Albert Hoenekopp, MD, Yaping Shou, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Gianantonio Rosti, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2755.

https://doi.org/10.1182/blood.V118.21.2755.2755

Published: 2011

Journal Articles

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Richard A. Larson, MD, Udomsak Bunworasate, MD, Anna G. Turkina, MD, PhD, Stuart L. Goldberg, MD, Pedro Dorlhiac-Llacer, MD, Jose L. Lopez, MD, Hagop M. Kantarjian, Giuseppe Saglio, MD, Andreas Hochhaus, MD, Albert Hoenekopp, MD, Rick E. Blakesley, PhD, Richard Yu, Neil J. Gallagher, MD, PhD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS

Blood (2011) 118 (21): 3768.

https://doi.org/10.1182/blood.V118.21.3768.3768

Published: 2011

Journal Articles

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Jennifer L Beaumont, MS, Cindy Nowinski, MD PhD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Rick E. Blakesley, PhD, Neil J. Gallagher, MD, PhD, James Burns, MS, David Cella, PhD

Blood (2011) 118 (21): 1025.

https://doi.org/10.1182/blood.V118.21.1025.1025

Published: 2011

Journal Articles

Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Andreas Hochhaus, MD, Gert Ossenkoppele, MD, PhD, Josy Reiffers, MD, Ming Yao, MD, Hirohiko Shibayama, MD, PhD, Norbert Gattermann, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, MD, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Clarisse Lobo, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 114.

https://doi.org/10.1182/blood.V118.21.114.114

Published: 2011

Journal Articles

Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Giuseppe Saglio, MD, Philipp D. LeCoutre, MD, Ricardo Pasquini, MD, Saengsuree Jootar, Hirohisa Nakamae, MD, PhD, Ian W. Flinn, MD, PhD, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Dong-Wook Kim, Hagop M. Kantarjian

Blood (2011) 118 (21): 452.

https://doi.org/10.1182/blood.V118.21.452.452

Published: 2011

Journal Articles

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Jorge E. Cortes, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla-Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani

Blood (2011) 117 (21): 5600–5606.

https://doi.org/10.1182/blood-2010-11-318949

Published: 2011

NARROW

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Email alerts

ASH Publications

American Society of Hematology

The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only